Clinical trials: Pancreas Carcinoma
Pancreatic Cancer
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, demcizumab (OMP-21M18), when given in combination with gemcitabine with or without (+/-) Abraxane®.
- Trial name
- NCT01189929
- Testing
- Demcizumab, Abraxane®, Gemcitabine
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 57 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Locally Advanced or Metastatic Pancreatic Cancer
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Objectives Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib
- Trial name
- NCT01181245
- Testing
- FG-3019
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Kyntra Bio
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Pancreatic Cancer
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
- Trial name
- NCT00614601
- Testing
- HyperAcute(R)-Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NewLink Genetics Corporation
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
- Trial name
- NCT03906357
- Testing
- Pemigatinib
- Sponsor
- Incyte Corporation
Cancer, Pancreatic Cancer
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
The objectives of this study are: To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients. To compare the safety and efficacy of CPI-613/Gemcitabine combination vs.
- Conditions
- Cancer, Pancreatic Cancer, Pancreatic Carcinoma
- Trial name
- NCT00907166
- Testing
- CPI-613, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cornerstone Pharmaceuticals
Pancreatic Cancer
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
- Trial name
- NCT02843945
- Testing
- Directional Brachytherapy Source Implant
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- CivaTech Oncology
Pancreatic Cancer
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer
This trial is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) in patients with pancreatic cancer.
- Trial name
- NCT05616494
- Testing
- Docetaxel for injection (Albumin-bound)
- Where
- China
- Volunteers
- 53 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Pancreatic Cancer
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF)…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
- Trial name
- NCT03490669
- Testing
- MSC-1
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Stage IV Pancreatic Cancer
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to…
- Trial name
- NCT01486329
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Vaximm GmbH
Solid Tumor Malignancies, Cancer, Solid Cancers
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with…
- Conditions
- Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT06883539
- Testing
- LXP1788 is administered intravenously via Port-A
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- LaunXP Biomedical Co., Ltd.
Pancreatic Cancer
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer
This is a multicenter, open-label, Phase II umbrella study conducted in participants with advanced or metastatic pancreatic cancer.
- Trial name
- NCT07814066
- Testing
- SKB571
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Pancreatic Tumor
Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor
This clinical trial is to evaluate the safety and impact on prognosis of personalized neoantigen peptide-based vaccines, which are based on next-generation sequencing and major histocompatibility complex affinity prediction…
- Trial name
- NCT03558945
- Testing
- Personalized neoantigen vaccine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Pancreatic Cancer
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Pancreatic carcinoma typically has a high recurrence rate and very poor prognosis. Surgery is the best choice for the treatment of pancreatic cancer, but for those advanced pancreatic cancer patients，when surgery is not…
- Trial name
- meso-CART (NCT02706782)
- Testing
- TAI-meso-CART
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.